SAMe to prevent liver cancer in MASLD-related cirrhosis
Part of Cancer, Digestive system clinical trials.
This trial tests if a supplement called SAMe can help prevent liver cancer in people with cirrhosis caused by MASLD (a fatty liver disease linked to metabolic issues). If you have MASLD, cirrhosis, and certain risk factors like diabetes or high blood pressure, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Diagnosed with MASLD (fatty liver disease with metabolic risk factors like high blood sugar, high blood pressure, or high cholesterol)
- Confirmed cirrhosis (scarring of the liver) from MASLD, not from other causes
- Limit alcohol to less than 7 drinks per week for men or less than 4.5 drinks per week for women
- Had a liver cancer screening (ultrasound, MRI, or CT) within the last 3 months
- No history of liver cancer, other liver diseases, or recent serious infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether ALN-PNP is safe and well tolerated, first in healthy adults and then in adults with MASLD (fatty liver disease). If you have MASLD, it may help researchers learn whether this medicine is a promising option for treating liver fat buildup.
This study is building a model to better predict how metabolic liver disease (MASLD) that has led to cirrhosis (scarring of the liver) will progress. If you have compensated cirrhosis (your liver is still working well) and have been diagnosed with MASLD or a related condition, this research could help develop more personalized care.
This study looks at whether breast or colorectal cancer survivors are more likely to develop a liver condition called MASLD (fatty liver disease not caused by alcohol). It uses blood tests, imaging, and possibly an MRI to check liver health.
This study looks at factors that predict liver cancer and the need for a liver transplant in people with a liver condition called MASLD (metabolic dysfunction-associated steatotic liver disease). The goal is to better understand the disease and improve care.
This study aims to understand the genetic factors behind metabolic fatty liver disease (MASLD) by comparing patients with advanced liver scarring or liver cancer to healthy blood donors. It may help doctors better predict and treat the disease in the future.
This study tests whether aspirin can help people with MASLD, a type of fatty liver disease linked to conditions like diabetes and obesity. It aims to see if aspirin can improve liver health without causing harm.
Hear when a new Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.